Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arbutus Biopharma Corporation - Common Stock
(NQ:
ABUS
)
4.620
-0.030 (-0.65%)
Official Closing Price
Updated: 4:15 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
902,026
Open
4.690
Bid (Size)
4.580 (500)
Ask (Size)
4.800 (29,700)
Prev. Close
4.650
Today's Range
4.595 - 4.730
52wk Range
2.705 - 5.100
Shares Outstanding
99,161,234
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
January 09, 2026
Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the...
Via
PredictStreet
Topics
Initial Public Offering
Intellectual Property
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Performance
YTD
-3.1%
-3.1%
1 Month
+0.7%
+0.7%
3 Month
+12.4%
+12.4%
6 Month
+45.7%
+45.7%
1 Year
+40.4%
+40.4%
More News
Read More
Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum
↗
October 21, 2025
Via
Chartmill
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
October 07, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus (ABUS) Q2 Revenue Surges 529%
↗
August 06, 2025
Via
The Motley Fool
Topics
Intellectual Property
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 06, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
June 25, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
May 07, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
April 23, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
March 27, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
March 03, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
February 25, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Provides 2025 Corporate and Financial Update
January 13, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
December 03, 2024
From
Whitefort Capital Management, LP
Via
Business Wire
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
November 26, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
November 20, 2024
Via
Benzinga
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
November 15, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
November 15, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
November 14, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
October 23, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
October 15, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
↗
October 03, 2024
Via
Benzinga
Topics
Intellectual Property
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 01, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Frequently Asked Questions
Is Arbutus Biopharma Corporation - Common Stock publicly traded?
Yes, Arbutus Biopharma Corporation - Common Stock is publicly traded.
What exchange does Arbutus Biopharma Corporation - Common Stock trade on?
Arbutus Biopharma Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arbutus Biopharma Corporation - Common Stock?
The ticker symbol for Arbutus Biopharma Corporation - Common Stock is ABUS on the Nasdaq Stock Market
What is the current price of Arbutus Biopharma Corporation - Common Stock?
The current price of Arbutus Biopharma Corporation - Common Stock is 4.620
When was Arbutus Biopharma Corporation - Common Stock last traded?
The last trade of Arbutus Biopharma Corporation - Common Stock was at 01/09/26 04:15 PM ET
What is the market capitalization of Arbutus Biopharma Corporation - Common Stock?
The market capitalization of Arbutus Biopharma Corporation - Common Stock is 458.12M
How many shares of Arbutus Biopharma Corporation - Common Stock are outstanding?
Arbutus Biopharma Corporation - Common Stock has 458M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
